Search Within

Issam S. Hamadeh

Formats
  1. Meeting Abstract (17)
  2. Journal Article (5)
  3. Review (2)
  4. Research Letter (1)
Groups
  1. Clinical Pharmacy Specialists (25)
  2. Hematologic Malignancies, Division of (23)
  3. Center for Hematologic Malignancies (22)
  4. Department of Medicine (22)
  5. Myeloma (22)
  6. Bone Marrow Transplant (21)

More Groups

People
  1. Carlyn Rose Tan (22)
  2. Sham Mailankody (22)
  3. Alexander Lesokhin (21)
  4. Hani Hassoun (21)
  5. Heather Landau (21)
  6. Kylee Maclachlan (21)

More People

Years
  1. 2025 (3)
  2. 2024 (15)
  3. 2023 (5)
  4. 2022 (2)
Publications
  1. Blood (10)
  2. Clinical Lymphoma, Myeloma and Leukemia (7)
  3. Blood Advances (5)
  4. Annals of Hematology (1)
  5. Cancer Management and Research (1)
  6. Frontiers in Oncology (1)
Publishers
  1. American Society of Hematology (15)
  2. Elsevier Inc. (7)
  3. Dove Medical Press Ltd (1)
  4. Frontiers Media S.A. (1)
  5. Springer (1)

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluating tumor-intrinsic and patient-specific mechanisms of resistance to teclistamab in anti-BCMA exposed and naïve multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I. S.; Wang, A.; Zhu, M.; Patel, D.; Tan, C.; Hultcrantz, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Patel, D.; Tan, C. R.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of polymorphisms in pharmacokinetic genes on tyrosine kinase inhibitor (TKI) tolerability in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
    Meeting Abstract

    Patel, J. N.; Lopes, K. E.; Druhan, L. J.; Zeng, H.; Beam, T.; Moore, D. C.; Salem, A.; Hamadeh, I.; Savage, Q.; Chojecki, A. L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world single center experience
    Meeting Abstract

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; Maclachlan, K. H.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C.; Akhlaghi, T.; more...
    Blood (2022)

    Fulltext@MSK | Save